|
1. Biologie
|
|
|
Radical new view of ovarian cancer implicates a ‘neglected’ origin [STAT]
|
|
|
|
|
|
Research
increasingly points to the likelihood that some of the most aggressive
ovarian cancers originate in the fallopian tubes. Most doctors now
believe there is little to lose by removing the tubes of women who are
done bearing children — and potentially much to gain in terms of cancer
prevention.
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
FDA drops black box warning on Pfizer's anti-smoking drug [Reuters]
|
|
|
|
|
|
Based
on the data, an independent panel to the FDA in September narrowly
voted in favor of removing the warning, arguing that the benefits of
Chantix outweighed the demerits of its side-effects and that there was
no clear evidence of causality between the drug and the side-effects.
|
|
|
|
|
|
|
3.4.1 Chimioprévention - aspirine
|
|
|
Regular Aspirin Use May Reduce Risk for Pancreatic Cancer [AACR]
|
|
|
|
|
|
Data
from the new study and meta-analysis of data from 18 other studies
suggest that over the past two decades, as the general population’s use
of aspirin has increased, the effect of aspirin in decreasing pancreatic
cancer risk has become more pronounced.
|
|
|
|
|
|
|
3.7 Alcool
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
Searching for a blood test to monitor ovarian cancer [Cancer Research UK]
|
|
|
|
|
|
While
these early results are positive, the researchers do point out a few
issues. First of all, the kind of trial they carried out is what’s known
as retrospective. This means that they didn’t plan the samples they
would collect ahead of time, rather they went back and looked at samples
that were already available and analysed them.
|
|
|
|
|
|
|
|
|
4.13 Dép., diag. & prono. - Peau
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5. Traitements
|
|
|
|
|
|
Early-phase trial demonstrates shrinkage in pediatric neural tumors [NCI]
|
|
|
|
|
|
In
an early-phase clinical trial of a new oral drug, selumetinib, children
with the common genetic disorder neurofibromatosis type 1 (NF1) and
plexiform neurofibromas, tumors of the peripheral nerves, tolerated
selumetinib and, in most cases, responded to it with tumor shrinkage.
NF1 affects 1 in 3,000 people.
|
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
Vaccine ‘nanodiscs’ could personalize cancer immunotherapy [FierceBiotech]
|
|
|
|
|
|
Each
nanodisc contains patient-specific tumor neoantigens, which are genetic
mutations in tumor cells, according to a press release. When given as a
vaccine, the nanodiscs prompt the immune system to generate
cancer-killing T cells that are preprogrammed to recognize the specific
tumor in that patient’s body.
|
|
|
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug [Xconomy]
|
|
|
|
|
|
Even
with this progress in ovarian cancer, the current reach of PARP
blockers remains limited. But it’s possible that could change over the
next few years. Pfizer, for instance, bought Medivation for $14 billion
in part for an experimental PARP blocker, talazoparib, being tested in
breast, lung, and prostate cancers. Tesaro’s niraparib is being tested
in breast cancer, and AstraZeneca is exploring olaparib’s use in a
variety of cancers as well.
|
|
|
|
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Kadcyla too expensive for routine funding on NHS [NICE]
|
|
|
|
|
|
The
drug, which costs around £90,000 per patient at its full list price, is
licensed to treat HER2-positive breast cancer which has spread to other
parts of the body, cannot be surgically removed and has stopped
responding to initial treatment.
|
|
|
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
U.S. melanoma rates keep rising [Reuters]
|
|
|
|
|
|
“The
incidences of melanoma in situ (the earliest form of melanoma) and thin
invasive tumors are increasing at a faster rate than that of thicker
tumors, and the five-year survival rates are also improving, which is
likely due to more melanomas being diagnosed at earlier stages.”
|
|
|
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.6 Publications
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|